FLT3-IN-12 is a potent, selective and orally activeFLT3kinase inhibitor withIC₅₀s of 1.48 nM and 2.87 nM forFLT3-WTandFLT3-D835Y, respectively. FLT3-IN-12 possesses high selectivity overc-KIT(>1000-fold). FLT3-IN-12 has an excellent anti-AML (acute myeloid leukemia) activity (MV4-11,IC₅₀of 0.75 nM)^[1].

IC50: 1.48 nM (FLT3-WT) and 2.87 nM (FLT3-D835Y)^[1]

FLT3-IN-12 (compound 36) efficiently inhibits the growth of multiple mutant BaF3 cells expressing FLT3-ITD, FLT3-D835V/F, FLT3-F691L, FLT3-ITD-F691L, and FLT3-ITD-D835Y with the IC₅₀range is 0.16-14.5 nM^[1].

Oral administration of FLT3-IN-12 (compound 36) at 6 mg/kg/d could significantly suppress tumor growth in the MV4-11 cell-inoculated xenograft model, exhibiting a tumor growth inhibitory rate of 95.1%. Importantly, FLT3-IN-12 could prolong the mouse survival time in the FLT3-ITD-TKD dual mutation syngeneic mouse model (BaF3-FLT3-ITD-D835Y) at a dose of 6 mg/kg p.o. bid/4W^[1].
FLT3-IN-12 (compound 36; 20 mg/kg; oral administration) exhibits excellent plasma exposure (area under the curve (AUC)_0–∞of 5278 ng·h/mL), T_1/2of 3.7 hours, and high maximum plasma concentrations (C_maxof 775 ng/mL)^[1].

432.44

C₂₁H₂₃F₃N₆O

2499966-67-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.